Oppenheimer Asset Management Inc. Sells 120,272 Shares of Pfizer Inc. $PFE

Oppenheimer Asset Management Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 37.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 199,634 shares of the biopharmaceutical company’s stock after selling 120,272 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Pfizer were worth $5,087,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of PFE. Cardinal Point Capital Management ULC increased its position in Pfizer by 0.7% during the third quarter. Cardinal Point Capital Management ULC now owns 314,272 shares of the biopharmaceutical company’s stock worth $8,008,000 after buying an additional 2,240 shares during the last quarter. Slagle Financial LLC increased its holdings in shares of Pfizer by 3.1% during the 3rd quarter. Slagle Financial LLC now owns 80,289 shares of the biopharmaceutical company’s stock valued at $2,046,000 after acquiring an additional 2,450 shares during the last quarter. Lantz Financial LLC raised its stake in shares of Pfizer by 28.5% in the 3rd quarter. Lantz Financial LLC now owns 45,324 shares of the biopharmaceutical company’s stock valued at $1,155,000 after acquiring an additional 10,042 shares in the last quarter. Canvas Wealth Advisors LLC acquired a new stake in Pfizer in the 3rd quarter worth approximately $271,000. Finally, German American Bancorp Inc. boosted its position in Pfizer by 4.6% during the third quarter. German American Bancorp Inc. now owns 136,112 shares of the biopharmaceutical company’s stock worth $3,468,000 after purchasing an additional 6,021 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 2.1%

Shares of PFE opened at $27.61 on Wednesday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.73. The firm has a market capitalization of $156.98 billion, a P/E ratio of 20.30 and a beta of 0.47. The company has a 50-day simple moving average of $25.70 and a 200-day simple moving average of $25.13. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter in the prior year, the firm posted $0.63 EPS. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA grants priority review for HYMPAVZI (marstacimab) sBLA — a near-term regulatory catalyst that could speed approval and future revenue potential if approved. Pfizer Inc. (PFE) announces FDA’s grant of priority review for HYMPAVZI® (marstacimab) sBLA
• Positive Sentiment: Pfizer to collect $29M from an SEC settlement tied to the 2013 SAC Capital matter — a small but tidy legal recovery that removes uncertainty and adds cash. Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund
• Positive Sentiment: Pfizer India reports strong Q3FY26 results (profit +11%, revenue +20%), signaling healthy regional execution and bolstering sentiment among EM investors. Pfizer shares gain 9% after Q3FY26 profit up 11%, revenue grows 20%
• Neutral Sentiment: Analyst takeaways from the Q4 call: Pfizer beat EPS and revenue estimates but reported weak COVID-related sales and provided cautious 2026 commentary — investors are parsing how much the pipeline and partnerships can offset near-term headwinds. 5 Revealing Analyst Questions From Pfizer’s Q4 Earnings Call
• Neutral Sentiment: Pfizer is a trending / widely watched stock; commentary focuses on income appeal (high yield) vs. growth uncertainty — useful for income investors but not a decisive growth thesis. Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: Analysis flags that pipeline progress and partnerships are being judged against a depressed valuation — investors remain skeptical about whether collaboration deals and late-stage assets will justify current multiples. Pfizer Pipeline Progress And Partnerships Tested Against Depressed Valuation
• Negative Sentiment: Independent analyst coverage warns of an approaching patent cliff and the need for a standout obesity franchise — risks that could pressure long-term growth absent clear pipeline wins. Pfizer: ‘Hold’ As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent analyst reports. Morgan Stanley dropped their price target on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. TD Cowen reiterated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a research note on Friday, October 31st. Finally, Bank of America cut their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $28.06.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.